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Summary
Osteoporosis is complicated by the occurrence of fragility
fractures. Over past years, various treatment options have
become available, mostly potent antiresorptive agents such
as bisphosphonates and denosumab. However, antiresorpt-
ive therapy cannot fully and rapidly restore bone mass and
structure that has been lost because of increased remod-
elling. Alternatively recombinant human parathyroid hor-
mone (rhPTH) analogues do increase the formation of new
bone material. The bone formation stimulated by intermit-
tent PTH analogues not only increases bone mineral dens-
ity (BMD) and bone mass but also improves the microar-
chitecture of the skeleton, thereby reducing incidence of
vertebral and nonvertebral fractures.
Teriparatide, a recombinant human PTH fragment available
in Switzerland, is reimbursed as second-line treatment in
postmenopausal women and men with increased fracture
risk, specifically in patients with incident fractures under
antiresorptive therapy or patients with glucocorticoid-in-
duced osteoporosis and intolerance to antiresorptives. This
position paper focuses on practical aspects in the manage-
ment of patients on teriparatide treatment. Potential first-
line indications for osteoanabolic treatment as well as the
benefits and limitations of sequential and combination ther-
apy with antiresorptive drugs are discussed.
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Introduction
For the treatment of osteoporotic patients two different
classes of drugs are being used: antiresorptives and os-
teoanabolics. Parathyroid hormone (PTH1–84;not available
in Switzerland) and its fully active fragment PTH1–34 (teri-
paratide) represent the only available osteoanabolic drugs
for osteoporosis treatment at present. Teriparatide is a re-
combinant formulation of endogenous PTH, containing a
34 amino-acid sequence which is identical to the N-termin-
al portion of the human hormone (rhPTH1–34) [1].
Osteoanabolic agents are an attractive therapeutic option
because of their direct stimulation of bone formation, an
action not shared by any current antiresorptive drug. The
bone formation induced by PTH analogues not only in-
creases bone mineral density (BMD) and bone mass but
also improves the microarchitecture of the skeleton,
thereby leading to improved bone strength and increased
mechanical resistance. Controlled trials have shown that
PTH1–34 significantly reduces the incidence of vertebral
and nonvertebral fractures [1, 2]. The beneficial effect of
teriparatide on hip fracture incidence, however, remains
unknown as the study by Neer et al. was not sufficiently
powered to address site-specific incidence of nonvertebral
fractures [2]. A current concept regarding the mode of ac-
tion of teriparatide is related to its ability to stimulate pro-
cesses associated with bone formation before it stimulates
processes associated with bone resorption. This sequence
of events has led to the concept of the anabolic window, the
period of time when teriparatide is maximally anabolic [3].
In Switzerland, teriparatide is reimbursed as second-line
treatment in postmenopausal women and men with osteo-
porosis and increased fracture risk, specifically in patients
with incident vertebral fracture during treatment with anti-
resorptive drugs. Furthermore, teriparatide is approved for
the treatment of adults with glucocorticoid-induced osteo-
porosis (GIOP) and increased fracture risk if antiresorpt-
ives are not tolerated or contraindicated.
After a first position paper on the indication for teriparatide
treatment in Switzerland published in 2011 in this journal
[4], a panel of Swiss internists, endocrinologists and
rheumatologists specialised in the treatment of osteoporos-
is (who also coauthored this position paper) met in March
2013 to discuss the following research questions regarding
the use of teriparatide in clinical practice:
– What is the definition of treatment failure in
osteoporosis (i.e., when should teriparatide be
prescribed as second-line therapy)?
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– Alternatively, which patients would benefit from first-
line treatment with an osteoanabolic drug?
– What are the benefits and limitations of the use of
teriparatide as (a) sequential therapy in patients with
prior antiresorptive treatment, (b) as add-on
(combination) to prior antiresorptive therapy, and (c)
as a de-novo combination therapy in previously
untreated patients?
Treatment failure in osteoporosis
The efficacy of an antiresorptive treatment in osteoporosis
is based on the demonstration of a reduction in the incid-
ence of new fractures supported by a significant increase in
BMD and a decrease in bone turnover markers. Specific-
ally for an individual patient the question arises whether
therapeutic agents, such as bisphosphonates, are effective
once nonadherence is excluded. As observed in placebo-
controlled trials, fractures occur in both placebo and act-
ively treated patients. An effective intervention decreases
the risk of fracture but does not eliminate the risk. Usually
risk reductions are in the range of 30%–70% for verteb-
ral fractures, 40%–50% for hip fractures and 15%–25% for
nonvertebral fractures [5, 6]. Thus fractures alone during
the course of treatment cannot be taken as proof of treat-
ment failure [7]. Furthermore, the use of intermediate en-
dpoints / surrogate measures to evaluate improvements in
bone strength does not necessarily well correlate with frac-
ture risk reduction. Hence, the relationship between change
in BMD and fracture risk is not linear and is affected
differently by the various antiresorptives, whether oral or
intravenous bisphosphonates or subcutaneous denosumab
[8–11]. Hence, changes in BMD alone do not explain the
antifracture efficacy of treatment: some patients with un-
changed or even decreased BMD may still have some de-
crease in fracture risk [12].
Recently, a working group of the Committee of Scientific
Advisors of the International Osteoporosis Foundation
(IOF) published a set of criteria to define failure to respond
to antiosteoporotic treatment [7]. If nonadherence and oc-
cult causes of secondary osteoporosis are excluded, the fol-
lowing circumstances have been proposed to define treat-
ment failure: (a) two or more incident fragility fractures,
(b) one incident fracture and elevated bone turnover mark-
ers at baseline with no significant reduction during treat-
ment (with an antiresorptive), a significant decrease in
BMD, or both, and (c) both no significant decrease in bone
markers and a significant decrease in BMD. Significant
changes in surrogate markers as an indicator of failure to
respond to treatment are defined as decrease in bone mark-
ers less than the least significant change (LSC; for bone re-
sorption markers this corresponds to a decrease of less than
20%–30% from baseline) and a decrease in BMD greater
than the LSC (for BMD this corresponds to a decrease of
more than 4%–5% from baseline) (table 1).
Accordingly, teriparatide could be indicated to replace an
antiresorptive drug not only in presence of a new vertebral
fracture, but under any of those circumstances. However
we recognise that the proposed definition of treatment fail-
ure (above) is not strongly evidence based. On another side,
randomised controlled trials of teriparatide have shown
fracture risk reduction in a large range of patients, inde-
pendent of their baseline risk.
Potential use of teriparatide as first-
line treatment option
The need for daily self-injection and the much higher cost
compared with other forms of treatment limit the wide-
spread use of PTH analogues. In most countries, PTH ther-
apy is indicated for treatment in severe osteoporosis. Spe-
cifically, in Switzerland PTH1–34 (teriparatide) is reim-
bursed in men and postmenopausal women who continue
to fracture (vertebral fractures only) despite adequate anti-
resorptive treatment and in patients with GIOP and intoler-
ance or contraindications to bisphosphonates (second-line
treatment). Although the safety and efficacy of teriparatide
have been studied beyond 2 years of treatment, the gener-
ally approved duration of therapy is limited to 2 years [13].
Therapy with antiresorptive agents causes refilling of the
remodelling space, an increase in secondary mineralisation
and stabilisation of bone architecture, which improves bone
strength and thereby reduces the incidence of fractures.
However, antiresorptive therapy is unlikely to rebuild bone
structure that has been lost as a result of increased bone
remodelling. Moreover, in patients with advanced osteo-
porosis, in whom considerable thinning of the trabecular
network has already taken place, the antifracture efficacy
of antiresorptives may be limited [14]. Hence, owing to
their ability to increase the production of new bone via dir-
ect and indirect anabolic effects on osteoblasts [15], rhPTH
analogues may offer a unique treatment alternative in pa-
tients with advanced osteoporosis. As such, potential can-
didates for first-line treatment with teriparatide include pa-
tients with severe osteoporosis and high fracture risk. We
suggest a definition of patients with high fracture risk in-
cluding those with (a) a low BMD (T-score <−2.5 standard
deviations [SD]) and prevalent vertebral fractures or ma-
jor nonvertebral fragility fractures, (b) patients with a very
low T-score of ≤−3.5 SD (in absence of fragility fractures
or other risk factors), and (c) patients with a low BMD (T-
score <−3 SD) and additional risk factors, including ad-
vanced age and glucocorticoid therapy (table 2). A major
effect of glucocorticoids on the skeleton is a decrease in
bone formation and unchanged or enhanced bone resorp-
tion. General current guidelines recommend bisphosphon-
ates as first-line agents in the prevention and treatment of
GIOP, but as reduction of osteoblast function is a major
determinant of GIOP, it appears logical to consider treat-
ment with a bone-forming agent. It has been shown that
teriparatide is an effective treatment of GIOP. In a random-
ised, double-blind trial, patients with GIOP were treated
Table 1: Circumstances defining treatment failure in patients on
antiresorptive therapy.
Occurrence of
– two or more incident fragility fractures
– one incident fracture and elevated bone turnover markers at
baseline with no significant reduction during treatment, a significant
decrease in BMD, or both
– no significant decrease in bone markers and a significant decrease
in BMD
BMD = bone mineral density
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with teriparatide or alendronate for 36 months [16]. This
trial confirmed the favourable effects of rhPTH (greater in-
crease in BMD and lower incidence of vertebral fractures
than with alendronate) which had already been demon-
strated in an 18-months trial [17].
A special group of patients for whom first-line teriparatide
could also be beneficial is men and women with idiopathic
osteoporosis ‒ bone fragility at a younger age and after ex-
clusion of a secondary cause [18]. The most consistent ab-
normalities noted in men with idiopathic osteoporosis are
decreased sex hormone levels (due to an increase in serum
sex hormone-binding globulin) as well as decreased cir-
culating insulin-like growth factor-1 (IGF-1) levels, which
may contribute to impaired bone formation [19]. Hence,
anabolic agents may correct the underlying defect in osteo-
blast function [20]. Trials show that daily subcutaneous ad-
ministration of teriparatide increases BMD of the spine and
femoral neck [21] and decreases vertebral fracture risk [22]
in men with osteoporosis.
Sequential and combination therapy
with rhPTH
Recent data on the effect of sequential and combination
therapy with osteoanabolic and antiresorptive drugs are of
importance.
We addressed the following questions regarding sequential
and combination therapies:
– Is there an influence of previous antiresorptive treatment
on subsequent response to rhPTH?
– In patients previously treated with antiresorptives, is it
better to add teriparatide or to switch to teriparatide
alone?
– Because teriparatide is approved only for 2 years of
treatment, is it necessary to follow this treatment
course with an antiresorptive drug?
– In treatment-naïve patients, can one use simultaneously
de-novo osteoanabolic and antiresorptive agents in a
manner that will expand the anabolic window?
Sequential therapy
Owing to its use as second-line treatment in women and
men with increased fracture risk, most patients who com-
mence teriparatide treatment have previously received an-
tiresorptive drugs. There are several studies investigating
the sequential strategy, i.e. switching from an antiresorptive
drug such as oral bisphosphonates or raloxifene to rhPTH
[23–26]. In the OPTAMISE study patients on bisphosphon-
ate (risedronate or alendronate) therapy for at least 2 years
where switched to daily PTH1–34 for 1 year [24, 27–29].
Significant differences in serum levels of the bone forma-
tion marker procollagen type 1 amino-terminal propeptide
(P1NP) between previously risedronate- and alendronate-
Table 2: Potential candidates for first-line treatment with teriparatide.
Patients with high fracture risk, including
– Low BMD (T-score <−2.5 SD) and prevalent vertebral (≥2 vertebral
fractures, Genant grade 2 and 3) or hip fracture
– Low BMD (T-score <−3.0 SD) and additional risk factors (i.e.,
advanced age, glucocorticoid treatment)
– Low BMD (T-score <−3.5 SD)
BMD = bone mineral density; SD = standard deviation
treated patients were seen as soon as 1 month, with a
more pronounced response to teriparatide in patients previ-
ously treated with risedronate as compared with alendron-
ate. Lumbar spine BMD showed significant differences in
percentage changes from baseline between prior bisphos-
phonate groups after one year. The more pronounced ef-
fect on BMD in patients previously treated with risedro-
nate may be explained by the differences in binding af-
finities between risedronate and alendronate. At the total
hip, quantitative computed tomography (QCT) showed that
there was a greater increase in the volumetric trabecular
BMD in patients pretreated with risedronate. However, as
the integral total hip volumetric BMD did not change, con-
comitant loss in cortical bone mass has to be assumed.
The prospective, randomised open-label EUROFORS
study included women with advanced postmenopausal os-
teoporosis (mean spine T-score –3.3 SD and at least one
vertebral or nonvertebral fracture) who had no previous bi-
sphosphonate treatment (n = 84) and those who had been
treated with bisphosphonates prior to teriparatide (n = 419)
[16, 21]. A subgroup of the previously treated patients was
classified as therapy failure (n = 285), defined either clin-
ically as occurrence of a fracture or according to densit-
ometry as inadequate increase in BMD despite continued
treatment for a median 54 months. A continued, significant
increase in lumbar spine and hip BMD was observed over
the 24-month period of treatment with the highest values
seen after 2 years. The mineral content at the lumbar spine
increased by 10.5% (p <0.001) in the entire group and by
9.8% in patients with an inadequate effect of previous bi-
sphosphonate therapy (p <0.001). Graeff et al. used finite
element analysis-based strength measures on 44 patients
out of the EUROFORS population to monitor teriparatide
effects on whole bone and local fracture risk [30]. Finite
element analysis-based strength and stiffness calculations
for three different load cases (compression, bending, and
combined compression and bending) were compared with
volumetric BMD and apparent bone volume fraction, as
well as dual-energy X-ray absorptiometry-based areal
BMD of the lumbar spine. Highly significant improve-
ments in all analysed variables as early as 6 months after
starting teriparatide were found. Treatment with teripar-
atide led to bone strength increases for different loading
conditions of close to 30%. Borggrefe et al. studied the
changes in bone distribution, geometry, and bone strength
based on three-dimensional QCT of the femoral neck in
52 subjects receiving teriparatide during the EUROFORS
study [31]. They showed that the cortical area started to in-
crease after 12 months and showed a significant increase
of 4.4% compared with baseline after 24 months of treat-
ment (p <0.01). Since there was no increase in total area,
this finding can be interpreted as the result of apposition
at the endosteal surface. Overall, in the course of treatment
no significant differences between the subgroups with or
without prior antiresorptive treatment could be detected.
Thus, rhPTH treatment is effective in increasing bone
formation, BMD and bone strength after prior long-term
exposure to antiresorptive therapies. In addition, the
EUROFORS and other studies demonstrate that duration of
previous antiresorptive therapy and time between stopping
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previous therapy and starting teriparatide did not affect the
BMD response at any skeletal site [32, 33].
Another approach in sequential therapy would be adding
rhPTH therapy to on-going antiresorptive treatment. Lind-
say et al showed that, in postmenopausal women, adding
teriparatide to on-going hormone replacement therapy res-
ulted in a superior gain in BMD compared with women
continuing oestrogen supplementation only [34]. Similarly,
Cosman et al. found that adding PTH1–34 to alendronate
was also associated with increases in BMD above the effect
of alendronate alone [35].
In a randomised open-label study, Cosman et al. compared
the effect of switching versus adding to teriparatide in post-
menopausal women on treatment with either raloxifene or
alendronate for at least 18 months [26]. Interestingly, the
response to teriparatide differed depending on whether the
prior antiresorptive agent was continued or stopped. The
biochemical bone turnover response to teriparatide was re-
duced in add versus switch patients. In contrast, the bone
density responses were greater in add versus switch pa-
tients in both spine and hip in the alendronate group and
in the hip in the raloxifene group. This superior effect on
BMD with the add regimen might be due to the fact that,
although absolute increase in bone markers were lower
with the add regimen, the anabolic window (the difference
between increases in bone formation over bone resorption)
was greater with the add regimen [32]. However, whether
regimens of switching to, as opposed to adding, teriparatide
results in a significant effect on fracture risk reduction re-
mains to be determined.
Finally, observational studies suggest that BMD decreases
more or less rapidly in individuals who do not take anti-
resorptive agents after cessation of rhPTH, whereas anti-
resorptive therapy after rhPTH treatment can maintain or
enhance rhPTH-induced BMD gain further [22, 36–39]. In
a controlled trial, patients with osteoporosis treated for 1
year with PTH1–84 were subsequently randomly allocated
to receive alendronate or placebo for an additional year
[40]. Over 2 years, women who received alendronate after
PTH1–84 therapy had significant increases in spine BMD of
12.1% compared with 4.1% in women treated with placebo
after PTH treatment. BMD at the hip was increased above
baseline in all groups except those receiving PTH followed
by placebo. Following PTH1–84 therapy with alendronate
consolidated the gains in bone mass obtained during treat-
ment with PTH1–84 alone. Hence, sequential therapy, with
bisphosphonate therapy after rhPTH treatment, is mandat-
ory although the benefits in terms of fracture risk reduction
remain speculative [1].
Combination therapy
In the Parathyroid Hormone and Alendronate (PATH)
study, 238 postmenopausal women with low BMD were
randomly assigned to daily treatment with PTH1–84, alen-
dronate or both for 12 months [41]. The areal BMD at
the spine increased in all treatment groups and did not
differ significantly between the PTH1–84 and the PTH1–84
plus alendronate group. P1NP increased markedly in the
PTH1–84 group but not in the combination therapy group,
which does not suggest a synergy between PTH and alen-
dronate. The volumetric density of trabecular bone at the
spine increased more with parathyroid hormone alone than
with combination therapy or alendronate alone. In the PTH
group, the volumetric density of cortical bone decreased,
an effect prevented by the combination treatment with alen-
dronate, indicating that alendronate might counteract ef-
fects of PTH on cortical porosity [41]. The observed in-
crease in cortical volume therefore might predominantly be
due to trabecularisation on the endocortical bone surface.
These results support those observed in men treated with
alendronate, PTH1–34 or both [42]. Alendronate therapy
was given for 30 months, and teriparatide was started after
the first 6 months. BMD of the lumbar spine and femoral
neck increased significantly more in men treated with
PTH1–34 alone than in those in the other two groups.
In contrast to these studies using oral bisphosphonates, di-
vergent effects in combination regimens using parenteral
zoledronate or denosumab have been observed. In a ran-
domised, partially double-blind trial, Cosman et al. invest-
igated the effects of combination therapy with a single in-
fusion of zoledronic acid and daily PTH1–34 versus either
agent alone on BMD and bone turnover markers [43]. In
the combination group, spine BMD increased more rapidly
than with either agent alone. Moreover, the combination
therapy increased total hip BMD more than the monother-
apies after 13 weeks, with final increments of 2.3%, 1.1%
and 2.2% at 1 year in the combination, PTH1–34 and zole-
dronic acid groups, respectively. The study is limited by
its short duration and insufficient power for fracture out-
comes.
Interestingly, bone turnover markers decreased rapidly, but
only transiently (<6 months), when teriparatide was com-
bined with a single infusion of zoledronic acid. This find-
ing is in contrast to studies using oral bisphosphonates
daily (alendronate 10 mg) [41, 42], which resulted in a sus-
tained reduction in bone turnover markers, and might ex-
plain differences in initial gain in BMD across the studies.
Recently, a similar approach has been investigated using
PTH1–34 in combination with denosumab (60 mg subcu-
taneously 6–monthly) versus either drug alone [44]. The
combination of teriparatide and denosumab led to a signi-
ficantly larger increase in spine and hip BMD after 6 and
12 months as compared with either drug alone.
In summary, the effects of combination strategies seem to
depend on the type of antiresorptive and its mode of ad-
ministration – that is, they depend on the pharmacodynam-
ic profile of the drug – with potentially superior addit-
ive effects of teriparatide when combined with zoledronic
acid or denosumab. Nevertheless and specifically as long
as fracture endpoint data are lacking, any possible benefits
of combination therapy must be weighed against the addi-
tional costs and inconveniences of taking two drugs rather
than one.
Implications for the use of
teriparatide in clinical practice
As osteoporosis is mostly due to bone loss, antiresorptive
therapy, mainly bisphosphonates, are a cornerstone of ther-
apy. However, as a result of their different mode of action,
anabolic drugs have increased our options in the treatment
of osteoporosis. Postmenopausal women and men with
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severe and progressive osteoporosis despite antiresorptive
therapy (“treatment failure”, see above) as well as patients
with GIOP need to be evaluated for a treatment course with
osteoanabolic drugs. At present, only teriparatide (For-
steo®, 20 μg subcutaneously) is available in Switzerland.
However, in future anabolic alternatives (such as anti-scler-
ostin antibodies) might become available. Teriparatide is
reimbursed for second-line treatment for a treatment course
of 24 months. Afterwards, sequential therapy with an anti-
resorptive drug following teriparatide to maintain increases
in bone mass and support secondary mineralisation of
newly formed bone is strongly recommended.
In clinical practice most patients are pretreated with anti-
resorptive agents before starting teriparatide. According to
the current evidence, switching to teriparatide or combin-
ing it with an antiresorptive therapy seems to provide addi-
tional benefits regarding different intermediate parameters
of skeletal integrity such as BMD, bone strength and stiff-
ness. However, it must be noted that, regarding the use of
combined or sequential therapy, no trial exists with frac-
ture as primary endpoint, and we are thus only referring
to surrogate markers of bone health. The OPTAMISE and
EUROFORS trials showed that prior antiresorptive treat-
ment only modestly blunted the BMD response to teripar-
atide. Any delay due to previous antiresorptive therapy, if
present, is overcome in terms of patient response to therapy
[32].
Overall, it remains unclear as to how and whether com-
bination or sequential therapy approaches can be used in a
manner that has advantages over rhPTH monotherapy. Re-
cent data on the effect of treatment regimens using teripar-
atide in combination with zoledronic acid or denosumab,
however, are noteworthy. It seems that combination ther-
apies with intravenous or subcutaneous antiresorptive
drugs result in only transient suppression of bone remod-
elling, as mirrored by transient decreases in bone turnover
markers. This might explain the more rapid and/or more
pronounced increase in BMD as compared with studies
using oral bisphosphonates (alendronate 10 mg daily).
Whether the use of weekly or monthly oral bisphosphon-
ates in combination with rhPTH also would attenuate an
anabolic window and, ultimately bone gain, is unknown.
In our opinion, patients with severe osteoporosis and high
fracture risk, including patients with multiple vertebral
fractures or very low BMD, could also be considered for
first-line osteoanabolic treatment. For these purposes and
for combination treatments, however, approval by health
insurers needs to be obtained prior to treatment, as the use
of teriparatide in Switzerland remains currently limited.
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